On one hand, CD4+ Tregs inhibit the activation, proliferation, and effector functions of various cell types, including NK cells, CD4+ T cells, CD8+ T cells, B lymphocytes, and DCs, thereby contributing to tumor metastasis and progression in different cancer types. Here, CD8A is linked to cancer.